ProShares UltraShort NASDAQ Biotechnology
10 hedge funds and large institutions have $6.05M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.12% more ownership
Funds ownership: 2.18% → 2.3% (+0.12%)
0% more capital invested
Capital invested by funds: $6.05M → $6.05M (+$1K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 11 → 10 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.56M |
| 2 |
HF
HRT Financial
New York
|
+$236K |
| 3 |
Jane Street
New York
|
+$168K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$165K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$43.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.04M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$316K |
| 3 |
VF
Virtu Financial
New York
|
-$270K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$68K |
| 5 |
Citigroup
New York
|
-$2.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HVC
1
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| $2.92M | +$1.56M | +9,375 | +100% |
|
|
WP
2
WealthSource Partners
San Luis Obispo,
California
| $1.11M | +$18.8K | +113 | +2% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $590K | +$43.2K | +260 | +7% |
|
|
4
Citadel Advisors
Miami,
Florida
| $488K | +$165K | +991 | +46% |
|
|
5
Jane Street
New York
| $366K | +$168K | +1,011 | +75% |
|
|
VF
6
Virtu Financial
New York
| $292K | -$270K | -1,622 | -46% |
|
|
HF
7
HRT Financial
New York
| $220K | +$236K | +1,418 | New |
|
|
8
Citigroup
New York
| $28K | -$2.16K | -13 | -7% |
|
9
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $27K | – | – | – |
|
|
10
Simplex Trading
Chicago,
Illinois
| $7K | -$316K | -1,898 | -98% |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.04M | -6,127 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$68K | -401 | Closed |
|
BIS Hedge Fund Activity: Q2 2018 in Review
10 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2018, worth a combined $6.05M — up 0.02% from $6.05M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Healthcare Value Capital, adding an estimated $1.56M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.04M sold.
- 10 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2018, down from 11 in Q1 2018.
- Funds reported $6.05M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2018, up 0.02% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2018 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2018 was Healthcare Value Capital, an estimated $1.56M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2018 was Susquehanna International Group, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2018.